(NASDAQ: WHWK) Whitehawk Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.71%.
Whitehawk Therapeutics's earnings in 2026 is -$115,806,000.On average, 8 Wall Street analysts forecast WHWK's earnings for 2026 to be -$64,263,476, with the lowest WHWK earnings forecast at -$84,810,974, and the highest WHWK earnings forecast at -$49,848,083. On average, 7 Wall Street analysts forecast WHWK's earnings for 2027 to be -$63,961,816, with the lowest WHWK earnings forecast at -$87,234,145, and the highest WHWK earnings forecast at -$43,097,822.
In 2028, WHWK is forecast to generate -$57,414,310 in earnings, with the lowest earnings forecast at -$84,810,974 and the highest earnings forecast at -$20,250,784.